{"id":"NCT01931839","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis","officialTitle":"A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-10","primaryCompletion":"2016-04","completion":"2016-04","firstPosted":"2013-08-29","resultsPosted":"2017-05-12","lastUpdate":"2017-05-12"},"enrollment":1164,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation"],"interventions":[{"type":"DRUG","name":"Lumacaftor Plus Ivacaftor Combination","otherNames":[]},{"type":"DRUG","name":"Ivacaftor","otherNames":[]}],"arms":[{"label":"Arm 1 Part A: LUM 600 mg qd/ IVA 250 mg q12h","type":"EXPERIMENTAL"},{"label":"Arm 2 Part A: Placebo - LUM 600 mg qd/ IVA 250 mg q12h","type":"EXPERIMENTAL"},{"label":"Arm 3 Part A: LUM 400 mg q12h/ IVA 250 mg q12h","type":"EXPERIMENTAL"},{"label":"Arm 4 Part A: Placebo - LUM 400 mg q12h/ IVA 250 mg q12h","type":"EXPERIMENTAL"},{"label":"Arm 5 Part A: Observational Cohort","type":"NO_INTERVENTION"},{"label":"Arm 6 Part B: LUM 400 mg q12h/ IVA 250 mg q12h","type":"EXPERIMENTAL"},{"label":"Arm 7 Part B: Placebo - LUM 400 mg q12h/ IVA 250 mg q12h","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of long-term treatment with lumacaftor in combination with ivacaftor in people 12 years and older with Cystic Fibrosis.","primaryOutcome":{"measure":"Part A Treatment Cohort: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","timeFrame":"Day 1 up to Week 105 (Study 105)","effectByArm":[{"arm":"Arm 1: Part A - LUM 600 mg qd/ IVA 250 mg q12h","deltaMin":331,"sd":null},{"arm":"Arm 2: Part A - Placebo- LUM 600 mg qd/ IVA 250 mg q12h","deltaMin":177,"sd":null},{"arm":"Arm 3: Part A - LUM 400 mg q12h/ IVA 250 mg q12h","deltaMin":333,"sd":null},{"arm":"Arm 4: Part A - Placebo- LUM 400 mg q12h/ IVA 250 mg q12h","deltaMin":176,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":166,"countries":["United States","Australia","Austria","Belgium","Canada","Czechia","Denmark","France","Germany","Ireland","Italy","Netherlands","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["37983082","33331662","28011037"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":156,"n":335},"commonTop":["Infective pulmonary exacerbation of cystic fibrosis","Cough","Sputum increased","Haemoptysis","Dyspnoea"]}}